Research Index

The 2026 Demirtaş review in International Journal of Molecular Sciences (doi:10.3390/ijms27188344) grades BPC-157's rodent IRI evidence as mechanistically coherent but structurally deficient. Every included study is non-GLP, rodent-only, and originates from a narrow authorship cluster. The review identifies oxidative stress attenuation, NO-pathway modulation, and endothelial stabilisation as its mechanistic pillars — while flagging absent independent replication as the structural weakness.

As of 2026, no completed randomised controlled trial has evaluated BPC-157 in any tissue-healing indication in humans. Existing human data are limited to small, uncontrolled, unblinded gastrointestinal studies that fail regulatory acceptance standards. Adverse-event signals from real-world compounded use include immunogenicity risk from impurity-amplified aggregation, FAERS-captured hospitalisations, and an unquantified oncogenic concern tied to VEGFR2-mediated angiogenesis.

A 2026 critical review in International Journal of Molecular Sciences (Demirtaş, MDPI, doi:10.3390/ijms27188344) synthesises rodent ischemia–reperfusion injury (IRI) evidence for BPC-157 across skeletal muscle, liver, kidney, and lung. The peptide consistently attenuates oxidative stress markers, suppresses apoptotic signalling, and preserves microvascular integrity — but every study is non-GLP, rodent-only, and single-laboratory, placing the entire body of work at preclinical-evidence grade.

BPC-157's physicochemical profile — a 1,419 Da linear pentadecapeptide with unusual gastric acid stability and a sub-16-minute intravenous half-life in rats — simultaneously constrains and directs formulation strategy. Mateescu and colleagues' 2026 critical review in Pharmaceutics (doi:10.3390/pharmaceutics18050625) concludes oral delivery for gastrointestinal indications is the most defensible near-term route, while parenteral development is blocked by uncharacterised aggregation, impurity, and immunogenicity parameters.

Yes. Across both TRIUMPH-1 and TRIUMPH-2, retatrutide's triple GIP, GLP-1, and glucagon receptor agonism produced weight-loss and glycaemic outcomes exceeding published GLP-1 monotherapy benchmarks. The mechanistic advantage lies in the glucagon receptor's thermogenic and hepatic contributions. These are pathways that GLP-1R agonism alone cannot access at therapeutic doses.

A 2026 critical review in Pharmaceutics by Mateescu and colleagues (doi:10.3390/pharmaceutics18050625) identifies the absence of validated analytical methods for BPC-157 as a structural bottleneck that simultaneously blocks pharmacokinetic characterisation, pharmaceutical stability testing, impurity profiling, GMP batch release, and potency assay development. No other gap in BPC-157's development programme cascades across this many domains at once.